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Fifteen years ago, in a series of elegant
studies, Hackstadt and colleagues showed
that the obligate intracellular bacteria
Chlamydia trachomatis save on their lipid
needs by incorporating sphingomyelins
(SMs) made by their host [1–3]. Shortly
after, Hatch and McClarty’s teams report-
ed that several eukaryotic glyceropho-
spholipids are also trafficked from the host
to the bacteria, which replace host-syn-
thesized straight-chain fatty acids by their
own branched-chain fatty acids [4]. Even
cholesterol, a lipid rarely found in bacte-
ria, was shown to accumulate in Chlamydia
[5]. As a result of this intense exploitation
of host lipids, the composition of the
bacterial membrane is closer to that of a
eukaryotic cell than to that of a prokaryote.
Throughout their developmental cycle,
chlamydiae reside within a membrane-
bounded compartment, the inclusion.
How they acquire host lipids remains an
open question. Possible mechanisms stud-
ied so far involve vesicular trafficking from
host compartments, including vesicular
traffic out of the Golgi apparatus, fusion
with multivesicular body–derived vesicles,
and engulfment of lipid droplets [6]. Two
papers recently published in PLoS Pathogens
show that non-vesicular traffic is also in-
volved [7,8].
SMs are synthesized by the transfer of
phosphorylcholine to a ceramide in a
reaction catalyzed by SM synthases. When
added to infected cells, the fluorescent
probe C6-NBD-ceramide traffics through
the Golgi apparatus and rapidly accumu-
lates in the bacteria, in the form of SM
and not ceramide [1], indicating that the
probe is converted to SM by host SM
synthases before transport to the bacteria.
However, understanding SM acquisition
by the bacteria requires going one step
back, into ceramide transport. Both stud-
ies show that CERT, a lipid transfer
protein involved in non-vesicular endo-
plasmic reticulum (ER) to Golgi transport
of ceramide [9], and VAPA and VAPB, its
ER-resident partners, are enriched around
the inclusion membrane [7,8]. At the
ultrastructural level, Derre ´ and colleagues
observed CERT on the inclusion mem-
brane and VAPB on ER tubules in close
proximity to the bacteria-filled compart-
ment. By analogy with the ER-Golgi
membrane contact sites described for
non-vesicular transport of ceramide by
CERT (Figure 1), Derre ´ proposes that
ER-inclusion membrane contact sites al-
low for direct transfer of ceramide to the
inclusion. The group identified the inclu-
sion protein of bacterial origin IncD as a
specific binding partner for CERT [7].
For what purpose does ceramide traffic
to the inclusion? Bacteria accumulate an
estimated 50% of SM synthesized from
exogenously added ceramide [1]. There-
fore, while a role for ceramide per se on
the inclusion is not excluded, it is expected
that its conversion to SM should strongly
benefit the bacteria. There are SM
synthase genes in humans identified as
SMS1 and SMS2. SMS1 is found in the
trans-Golgi apparatus while SMS2 is
predominantly associated with the plasma
membrane. Elwell and colleagues show
that both enzymes are in close prox-
imity to the inclusion membrane, and
propose that the recruitment of CERT,
its ER binding partner VAPA, and SM
synthases establish an ‘‘on-site SM
factory’’ [8].
Like CERT, other lipid transfer/bind-
ing proteins have been described as
functional components of ER-Golgi mem-
brane contact sites. Future studies need to
address whether these non-vesicular lipid
transfer systems are involved in the acqui-
sition of phospholipids and sterols by the
inclusion. Such a direct transfer could
explain why transfer of host phospholipids
to the bacteria was unaffected by brefeldin
A, which inhibits Arf1-dependent vesicular
transit through the Golgi apparatus. It is
also consistent with the observation that
traffic of glycoproteins out of the Golgi is
not disrupted by infection [3].
In the presence of brefeldin A, SM
acquisition by the bacteria is reduced and
inclusions are smaller [1]. This observa-
tion and others argue for the existence of a
vesicular-mediated access of SM to the
inclusion [2]. The new data presented in
PLoS Pathogens do not speak against this
possibility, which can operate alongside
non-vesicular traffic. In fact, Elwell et al.
also provide data showing that depletion
of the brefeldin A target GBF1 reproduces
the effect of the drug on Chlamydia infec-
tion, implicating GBF1 in the vesicular
route for SM acquisition [8].
Interestingly, while brefeldin A (or
GBF1 depletion) only affect inclusion size,
and not bacterial proliferation, CERT (or
VAP) depletion have an impact on both
[7,8]. Does this mean that the non-
vesicular process makes a greater contri-
bution to total SM acquisition? This will
be difficult to assess with the methods used
currently. Due to rapid photobleaching,
quantification of the accumulation of fluo-
rescent probes by imaging is technically
challenging. Incidentally, the two studies
report divergent results on the effect of
CERT depletion on SM accumulation in
the inclusion assessed by this technique. In
addition to not being quantitative with the
probes currently available, imaging does
not give information on the possible modi-
fications of the fluorescent-tagged lipid in
the host or in the bacteria [4]. But more
than quantity, the site of SM acquisition at
the inclusion might determine its fate.
Elwell’s data suggest that the two path-
ways contribute to different aspects of the
developmental cycle of Chlamydia, CERT
being important for bacterial replication
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for inclusion growth and stability [8]. This
would imply that the SMs of different
origin constitute two distinct pools, either
because they consist of different molecules
and/or because they do not diffuse freely
on the inclusion and cannot be equally
taken up by the bacteria.
Both studies were conducted on the
human pathogen Chlamydia trachomatis.
Surprisingly, Derre ´ and colleagues report
that the guinea pig strain Chlamydia caviae
does not recruit CERT to its inclusion,
consistent with the absence of IncD in this
strain [7]. Is that so unexpected? We
already know that these obligate intracel-
lular bacteria have adopted multiple
redundant mechanisms to enter cells and
to intercept host intracellular traffic, to
give only two well-studied examples [6]. It
is hard to imagine that chlamydiae have
not put the same energy into exploiting all
possible steps of lipid transport in eukary-
otic cells.
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Figure 1. Direct transport of ceramide from the ER to C. trachomatis inclusion. At ER-Golgi membrane contact sites the ceramide transfer
protein CERT associates to the ER-resident proteins VAPA/VAPB and, via its PH domain, to PI4P at the trans-Golgi. Upon transfer by CERT, ceramide is
converted to SM by a SM synthase (SMS). In Chlamydia-infected cells, ER-inclusion membrane contact sites involving VAPA/VAPB and CERT are
observed. CERT interacts with the inclusion-anchored bacterial protein IncD through its PH domain but independently of PI4P. Upon transfer to the
inclusion membrane, ceramide might be converted to SM by host SMS, which is enriched around the inclusion, and incorporated by the bacteria.
Because the catalytic site of SMS is in the lumenal site of the Golgi apparatus, it would imply that the enzyme traffics to the inclusion membrane to
convert ceramide, by a mechanism that remains to be determined. Other possibilities for SM acquisition by the bacteria are discussed [8]. Alternative
routes for the transfer of SM and other lipids to the Chlamydia are discussed in an excellent recent review [6].
doi:10.1371/journal.ppat.1002208.g001
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